Novel molecular targets for prevention of obesity and osteoporosis

Journal of Nutritional Biochemistry

Volumn 22, Issue 12, 2011, Pages 1099-1104

  Rayalam, Srujana ^a   Yang, Jeong Yeh ^a   Della Fera, Mary Anne ^a   Baile, Clifton A ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Aryl hydrocarbon receptor; Farnesoid X receptor; H + ATP synthase; TGR5; Vitamin D receptor

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; AROMATIC HYDROCARBON RECEPTOR; CALCITRIOL; CALCITRIOL DERIVATIVE; CATECHIN; CURCUMIN; DAIDZEIN; FARNESOID X RECEPTOR; GENISTEIN; GUGGULSTERONE; HERBACEOUS AGENT; IPRIFLAVONE; KAEMPFEROL; PLANT MEDICINAL PRODUCT; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; QUERCETIN; VITAMIN D RECEPTOR; XANTHOHUMOL; XANTHOPHYLL;

ADIPOCYTE; ADIPOGENESIS; ADVERSE OUTCOME; BONE DEVELOPMENT; HERBAL MEDICINE; HUMAN; LIPOGENESIS; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PHYSICIAN; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADIPOGENESIS; HUMANS; LIPOGENESIS; MODELS, BIOLOGICAL; OBESITY; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; PHYTOTHERAPY; PLANT EXTRACTS; SIGNAL TRANSDUCTION;

EID: 81255134366     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.11.009     Document Type: Review

References (54)

1. Reyes M., Verfaillie C.M. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001, 938:231-233. [discussion 3-5].
2. de Simone G., D'Addeo G. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr Metab Cardiovasc Dis 2008, 18:337-341.
3. Gennari L., Merlotti D., Valleggi F., Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs 2009, 18:839-849.
4. Newman D.J., Cragg G.M., Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003, 66:1022-1037.
5. Rayalam S., Della-Fera M.A., Ambati S., Yang J.Y., Park H.J., Baile C.A. Enhanced effects of 1,25(OH)(2)D(3) plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring) 2008, 16:539-546.
6. Rayalam S., Della-Fera M.A., Ambati S., Boyan B., Baile C.A. Enhanced effects of guggulsterone plus 1,25(OH)2D3 on 3T3-L1 adipocytes. Biochem Biophys Res Commun 2007, 364:450-456.
7. Rayalam S., Yang J.Y., Della-Fera M.A., Park H.J., Ambati S., Baile C.A. Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes. J Med Food 2009, 12:846-853.
8. Blumberg J.M., Tzameli I., Astapova I., Lam F.S., Flier J.S., Hollenberg A.N. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J Biol Chem 2006, 281:11205-11213.
9. Wong K.E., Szeto F.L., Zhang W., Ye H., Kong J., Zhang Z., et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 2009, 296:E820-E828.
10. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 1994, 224:335-343.
11. Lechner D., Bajna E., Adlercreutz H., Cross H.S. Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. Anticancer Res 2006, 26:2597-2603.
12. Ohsawa M., Mizunuma H., Kagami I., Miyamoto S., Kanuma T., Ibuki Y. Effect of 1,25(OH)2D3 on expression of estrogen receptor-alpha mRNA on rat osteosarcoma cell line (ROS 17/2.8). Life Sci 2000, 66:2465-2472.
13. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
14. Drent M.L., van der Veen E.A. Endocrine aspects of obesity. The Netherlands journal of medicine 1995, 47:127-136.
15. Somjen D., Kaye A.M., Harell A., Weisman Y. Modulation by vitamin D status of the responsiveness of rat bone to gonadal steroids. Endocrinology 1989, 125:1870-1876.
16. Larijani B., Maghbooli Z., Hossein-nezhad A., Saghafi H., Behzadi H. The common role of vitamin D in osteoporosis and metabolic syndrome 2008.
17. Mizunuma H., Shiraki M., Shintani M., Gorai I., Makita K., Itoga S., et al. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss. J Bone Miner Metab 2006, 24:11-15.
18. Zhou Y.S., Liu Y.S., Tan J.G. Is 1, 25-dihydroxyvitamin D3 an ideal substitute for dexamethasone for inducing osteogenic differentiation of human adipose tissue-derived stromal cells in vitro?. Chinese medical journal 2006, 119:1278-1286.
19. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6:507-515.
20. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
21. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004, 113:1408-1418.
22. Ma K., Saha P.K., Chan L., Moore D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006, 116:1102-1109.
23. Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010, 51:771-784.
24. Shen H., Zhang Y., Ding H., Wang X., Chen L., Jiang H., et al. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 2008, 22:1-14.
25. Cui J., Huang L., Zhao A., Lew J.L., Yu J., Sahoo S., et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003, 278:10214-10220.
26. Suzuki T., Tamehiro N., Sato Y., Kobayashi T., Ishii-Watabe A., Shinozaki Y., et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J Pharmacol Sci 2008, 107:285-294.
27. Honjo Y., Sasaki S., Kobayashi Y., Misawa H., Nakamura H. 1,25-Dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J Endocrinol 2006, 188:635-643.
28. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009, 89:147-191.
29. Thomas C., Auwerx J., Schoonjans K. Bile acids and the membrane bile acid receptor TGR5 - connecting nutrition and metabolism. Thyroid 2008, 18:167-174.
30. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
31. Sato H., Genet C., Strehle A., Thomas C., Lobstein A., Wagner A., et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007, 362:793-798.
32. Foord S.M., Bonner T.I., Neubig R.R., Rosser E.M., Pin J.P., Davenport A.P., et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005, 57:279-288.
33. Tiwari A., Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today 2009, 14:523-530.
34. Gouveia C.H., Christoffolete M.A., Zaitune C.R., Dora J.M., Harney J.W., Maia A.L., et al. Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. Endocrinology 2005, 146:195-200.
35. O'Shea P.J., Bassett J.H., Sriskantharajah S., Ying H., Cheng S.Y., Williams G.R. Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor alpha1 or beta. Mol Endocrinol (Baltimore, Md) 2005, 19:3045-3059.
36. Tripathi Y.B., Malhotra O.P., Tripathi S.N. Thyroid stimulating action of Z-guggulsterone obtained from Commiphora mukul. Planta Med 1984, 50:78-80.
37. Radovic B., Schmutzler C., Kohrle J. Xanthohumol stimulates iodide uptake in rat thyroid-derived FRTL-5 cells. Mol Nutr Food Res 2005, 49:832-836.
38. Miura M., Tanaka K., Komatsu Y., Suda M., Yasoda A., Sakuma Y., et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem Biophys Res Commun 2002, 291:987-994.
39. Urizar N.L., Moore D.D. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 2003, 23:303-313.
40. Gu Y.Z., Hogenesch J.B., Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000, 40:519-561.
41. Schmidt J.V., Bradfield C.A. Ah receptor signaling pathways. Annu Rev Cell Dev Biol 1996, 12:55-89.
42. Mimura J., Yamashita K., Nakamura K., Morita M., Takagi T.N., Nakao K., et al. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 1997, 2:645-654.
43. Zhang S., Qin C., Safe S.H. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 2003, 111:1877-1882.
44. Alexander D.L., Ganem L.G., Fernandez-Salguero P., Gonzalez F., Jefcoate C.R. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci 1998, 111(Pt 22):3311-3322.
45. Naruse M., Ishihara Y., Miyagawa-Tomita S., Koyama A., Hagiwara H. 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo. Endocrinology 2002, 143:3575-3581.
46. Harper P.A., Riddick D.S., Okey A.B. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol 2006, 72:267-279.
47. Ohtake F., Takeyama K., Matsumoto T., Kitagawa H., Yamamoto Y., Nohara K., et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003, 423:545-550.
48. Singh S.U., Casper R.F., Fritz P.C., Sukhu B., Ganss B., Girard B., et al. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 2000, 167:183-195.
49. Stock D., Gibbons C., Arechaga I., Leslie A.G., Walker J.E. The rotary mechanism of ATP synthase. Curr Opin Struct Biol 2000, 10:672-679.
50. Kim B.W., Choo H.J., Lee J.W., Kim J.H., Ko Y.G. Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp Mol Med 2004, 36:476-485.
51. Arakaki N., Nagao T., Niki R., Toyofuku A., Tanaka H., Kuramoto Y., et al. Possible role of cell surface H+-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 2003, 1:931-939.
52. Zheng J., Ramirez V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 2000, 130:1115-1123.
53. Arakaki N., Kita T., Shibata H., Higuti T. Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs. FEBS Lett 2007, 581:3405-3409.
54. Rayalam S., Yang J.Y., Ambati S., Della-Fera M.A., Baile C.A. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res 2008, 22:1367-1371.